Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma-Reference-Cited by-同舟云学术

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

Published:2021-12-14 Issue: Volume: Page:
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Bishop Michael R.¹,Dickinson Michael¹,Purtill Duncan¹,Barba Pere¹,Santoro Armando¹,Hamad Nada¹,Kato Koji¹,Sureda Anna¹,Greil Richard¹,Thieblemont Catherine¹,Morschhauser Franck¹,Janz Martin¹,Flinn Ian¹,Rabitsch Werner¹,Kwong Yok-Lam¹,Kersten Marie J.¹,Minnema Monique C.¹,Holte Harald¹,Chan Esther H.L.¹,Martinez-Lopez Joaquin¹,Müller Antonia M.S.¹,Maziarz Richard T.¹,McGuirk Joseph P.¹,Bachy Emmanuel¹,Le Gouill Steven¹,Dreyling Martin¹,Harigae Hideo¹,Bond David¹,Andreadis Charalambos¹,McSweeney Peter¹,Kharfan-Dabaja Mohamed¹,Newsome Simon¹,Degtyarev Evgeny¹,Awasthi Rakesh¹,del Corral Christopher¹,Andreola Giovanna¹,Masood Aisha¹,Schuster Stephen J.¹,Jäger Ulrich¹,Borchmann Peter¹,Westin Jason R.¹^ORCID

Affiliation:

1. From the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC (M. Dickinson), Fiona Stanley Hospital, Murdoch, WA (D.P.), and the Department of Haematology, St. Vincent’s Hospital Sydney, and St. Vincent’s Clinical School, University of New South Wales, Sydney (N.H.) — all in Australia; Hospital Universitari Vall d’Hebron and Universitat Autònoma de Barcelona (P. Barba) and the Clinical...

Funder

Novartis Pharmaceuticals Corporation

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2116596

Cited by 232 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Programmed death-1 inhibitors as treatment for other subtypes of lymphomas not recommended in the guidelines: Real-world data from a single center in China;2024-02-06

2. Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study;The Lancet Haematology;2024-02

3. Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed / refractory large B-cell lymphoma: findings from a German monocentric study.;2024-01-16

4. Current development of chimeric antigen receptor T‐cell therapy for diffuse large B‐cell lymphoma and high‐grade B‐cell lymphoma;European Journal of Haematology;2024-01-03

5. Emerging Biomarkers for Monitoring Chimeric Antigen Receptor T-Cell Therapy;Clinical Chemistry;2024-01